close

Mylan releases generic version of Trilafon

1 min read
article image -

CANONSBURG – Mylan N.V. announced Thursday the U.S. launch of Perphenazine Tablets USP, in 2-, 4-, 8- and 16- mg doses, a generic version of the reference listed drug, Trilafon tablets, originally marketed by Schering. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product, which is used in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults.

Perphenazine tablets had U.S. sales of approximately $41 million for the 12 months ending Feb. 28, according to IMS Health.

CUSTOMER LOGIN

If you have an account and are registered for online access, sign in with your email address and password below.

NEW CUSTOMERS/UNREGISTERED ACCOUNTS

Never been a subscriber and want to subscribe, click the Subscribe button below.

Starting at $3.75/week.

Subscribe Today